| abstract |
The present invention relates to a compound having an α 1 -adrenergic receptor blocking action and useful as a therapeutic agent for dysuria. In the powder X-ray diffraction pattern, 2θ is 5.5 ° ± 0.2 °, 6.1 ° ± 0.2 °, 9.8 ° ± 0. .2 °, 11.1 ° ± 0.2 °, 12.2 ° ± 0.2 °, 16.4 ° ± 0.2 °, 19.7 ° ± 0.2 ° and 20.0 ° ± 0 The present invention relates to an oral solid pharmaceutical crystal characterized by a main peak of 2 ° and an oral solid pharmaceutical for treating urination disorder containing it as an active ingredient. |